Company overview

NOVOS leverages science and data to create the best nutraceuticals to extend human lifespan.We at NOVOS believe much more can be done to slow down aging through science, so we create the first supplements in the world that are:• Based on the best available science• Created with the world’s top experts in the aging field • Use scientifically validated ingredients that extend lifespan in various organisms• Focused on the 12 mechanisms of aging mechanisms to leverage synergistic effects • Include ingredients shown to have beneficial effects on aging in humansThe result is NOVOS, the best longevity supplements available.NOVOS’ scientific advisors are biochemists, geneticists and professors from Harvard, MIT, University of Liverpool, University of Washington, Salk Institute, and other universities & institutes around the world. Our scientists have received honors that include Breakthroughs in Gerontology Award, an Alzheimer’s Association New Investigator Award, and an Ellison Medical Foundation New Scholar in Aging Award. Each one of them is a pioneer in the longevity field and have been featured by 60 Minutes, TIME magazine, BBC, CNN, Science, Scientific American, Washington Post, New York Times, and countless other publications.NOVOS is a Public Benefit Corporation (PBC). A portion of our profits and equity is donated to nonprofits in the longevity science space, like the 501(c)(3), Life Extension Advocacy Foundation (LEAF).NOVOS also creates free content to educate people on how to live longer, healthier lives, even if they don’t use NOVOS, which you can find on our blog at NovosLabs.com.
Founded in 2018
New York, New York, USA

Salaries

Help build salary transparency at NOVOS

Share your compensation anonymously to see full data.

Contribute

People

Funding

Total funding

$3.2M

Last raise

Angel, 4 years ago

Funding history

Jan 2022

Angel Round NOVOS

Oct 2021

Pre Seed Round NOVOS · $3.2M

Jan 2021

Seed Round NOVOS

Audience

LinkedIn followers

Follower count and growth

Total followers

11.1K

12-mo growth

+11.4%

Monthly growth

+3.8%

News

Links